Showing 6771-6780 of 10186 results for "".
- Exuviance Introduces New Detox Mud Treatmenthttps://practicaldermatology.com/news/exuviance-introduces-new-detox-mud-treatment/2458001/Exuviance is rolling out their new Detox Mud Treatment. The Exuviance Detox Mud Treatment is formulated with three key ingredients: 23 percent Active Charcoal, Clay, and NeoGlucosamine® for a refined, smoother complexion. The patented no
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- Timing of Melanoma Diagnosis, Treatment Can Mean Life or Deathhttps://practicaldermatology.com/news/timing-of-melanoma-diagnosis-treatment-can-mean-life-or-death/2458004/The sooner melanoma patients are treated, the better their survival, particularly for stage I melanoma, according to a new study from the Cleveland Clinic. The research appears online today in the Journal of the
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- National Rosacea Society Awards New Grants; Call for 2018 Proposalshttps://practicaldermatology.com/news/national-rosacea-society-awards-new-grants/2458008/The National Rosacea Society (NRS) awarded funding for three new studies, in addition to continuing support for three ongoing studies, as part of its research grants program. Dr. Benjamin Kaffenberger, MD assistant professor of dermatology at the Ohio
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- Omar A. Ibrahimi, MD, PhD, Wins ASDS Award for Outstanding Servicehttps://practicaldermatology.com/news/omar-a-ibrahimi-md-phd-wins-asds-award-for-outstanding-service/2458022/Omar A. Ibrahimi, MD, PhD, of Stamford, Connecticut, took home the 2017
- Dermavant Sciences Appoints Vince Ippolito as President and COOhttps://practicaldermatology.com/news/dermavant-sciences-appoints-vince-ippolito-as-president-and-coo/2458034/Dermavant Sciences, a biopharmaceutical company focused on developing therapies for dermatologic conditions, appointed Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C